BCL2 and lymphoma: For example, hypermethylation of BCL-2, BAX, BAK, and PUMA promoter are implicated in prostate cancer, multiple myeloma, and lymphoma, highlighting the role of epigenetic alterations in apoptosis resistance [38,39,40].